May 4, 2017 7:30 am EDT EyeGate Submits Investigational Device Exemption (IDE) Filing for Second Pilot Study of Ocular Bandage Gel
Mar 13, 2017 7:30 am EDT EyeGate Pharma Strengthens Scientific Advisory Board with Appointments of Daniel S. Durrie, M.D. and Randall J. Olson, M.D.
Feb 23, 2017 4:08 pm EST EyeGate Pharmaceuticals Reports Full-year 2016 Financial Results and Provides Business Update
Jan 30, 2017 8:30 am EST EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects
Jan 24, 2017 8:30 am EST EyeGate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference
Jan 23, 2017 8:30 am EST EyeGate Pharma Awarded Canadian Patent for Proprietary Iontophoretic Formulation and Use of the Formulation for Ocular Delivery of Dexamethasone Phosphate
Jan 9, 2017 8:30 am EST EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437
Dec 5, 2016 8:30 am EST EyeGate Reports Positive Data from Third Stage of Phase 1b/2a Clinical Trial of EGP-437 in Cataract Surgery Patients
Nov 17, 2016 4:01 pm EST FDA Confirms a 510(k) De Novo Path for EyeGate’s Device, the Ocular Bandage Gel, Following Pre-Submission Meeting